Published in Health Policy on February 13, 2010
Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract (2012) 1.84
Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. J Gen Intern Med (2011) 1.75
Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Prefer Adherence (2013) 1.11
Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int (2011) 0.99
Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab (2013) 0.95
A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int (2013) 0.94
Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int (2013) 0.90
Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication. Osteoporos Int (2014) 0.87
Health technology assessment in osteoporosis. Calcif Tissue Int (2013) 0.85
Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis. Drugs Aging (2014) 0.80
Cost-effectiveness of enhancing adherence with oral bisphosphonates treatment in osteoporotic women: an empirical approach based on healthcare utilisation databases. BMJ Open (2014) 0.78
Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence. Patient Prefer Adherence (2016) 0.77
Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis. BMC Musculoskelet Disord (2017) 0.75
Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporos Int (2013) 0.75
Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. Rheumatology (Oxford) (2017) 0.75
Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am (2004) 7.59
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med (2003) 3.07
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 1.82
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum (2007) 1.65
Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr Med Res Opin (2012) 1.64
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab (2013) 1.60
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause (2004) 1.57
Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.54
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Strategies for the prevention of hip fracture. Am J Med (2003) 1.50
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. Bone (2008) 1.48
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (2008) 1.44
Controlled whole body vibration to decrease fall risk and improve health-related quality of life of nursing home residents. Arch Phys Med Rehabil (2005) 1.42
Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int (2005) 1.36
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab (2007) 1.32
Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am (2008) 1.27
Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage (2004) 1.25
Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res (2006) 1.20
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol (2008) 1.18
Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res (2003) 1.17
Quality of life in sarcopenia and frailty. Calcif Tissue Int (2013) 1.17
Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol (2011) 1.15
The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab (2014) 1.14
Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Prefer Adherence (2013) 1.11
Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Res Ther (2014) 1.11
Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother (2009) 1.10
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab (2012) 1.09
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res (2010) 1.08
Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging (2007) 1.07
New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage (2005) 1.06
D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clin Exp Res (2005) 1.06
Performance of osteoporosis risk assessment tools in postmenopausal women aged 45-64 years. Osteoporos Int (2004) 1.05
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord (2008) 1.04
Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol (2004) 1.03
The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis. J Rheumatol (2002) 1.02
Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int (2004) 1.01
Development of a clinical assessment tool in identifying Asian men with low bone mineral density and comparison of its usefulness to quantitative bone ultrasound. Osteoporos Int (2004) 1.00
Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol (2006) 0.99
Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int (2005) 0.99
Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clin Exp Res (2007) 0.98
Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin (2006) 0.97
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol (2008) 0.97
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin (2008) 0.96
Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics (2011) 0.96
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res (2004) 0.96
Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum (2013) 0.95
Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int (2008) 0.94
The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health (2012) 0.93
Age- and sex-stratified prevalence of physical disabilities and handicap in the general population. Aging Clin Exp Res (2004) 0.93
Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging (2006) 0.93
Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health (2011) 0.92
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin (2003) 0.92
Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. Calcif Tissue Int (2010) 0.92
Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res (2008) 0.92
Creatinine-or cystatin C-based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease. BMC Nephrol (2013) 0.92
Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone (2008) 0.91
Validity and reliability of the French version of the STarT Back screening tool for patients with low back pain. Spine (Phila Pa 1976) (2014) 0.91
Treatment of postmenopausal osteoporosis. BMJ (2005) 0.90
Comparison of a simple clinical risk index and quantitative bone ultrasound for identifying women at increased risk of osteoporosis. Osteoporos Int (2003) 0.90
Low dietary calcium in European postmenopausal osteoporotic women. Public Health Nutr (2008) 0.90
Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int (2003) 0.89
Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract (2014) 0.89
The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res (2012) 0.89
Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone (2010) 0.88
Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. Calcif Tissue Int (2011) 0.88
Osteoporosis and sarcopenia: two diseases or one? Curr Opin Clin Nutr Metab Care (2016) 0.87
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone (2011) 0.87
A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics (2015) 0.87
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women. Expert Rev Pharmacoecon Outcomes Res (2013) 0.86
Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. J Hypertens (2008) 0.86
How to define responders in osteoarthritis. Curr Med Res Opin (2013) 0.86
Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone (2008) 0.86
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. BMC Musculoskelet Disord (2008) 0.85
Mobile Phone-Connected Wearable Motion Sensors to Assess Postoperative Mobilization. JMIR Mhealth Uhealth (2015) 0.85
Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health (2010) 0.85
Translation validation of a new back pain screening questionnaire (the STarT Back Screening Tool) in French. Arch Public Health (2012) 0.85